TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22290521
Drug: Customized Power
Normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Customized Power Balance performance mouth guard (PB MG)
Study: 22290521
Drug: Regular over
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular over the counter boil-and-bite mouth guard (Reg MG)
Study: 22290521
Drug: No mouth
Approvals — FDA: no, EMA: no, PMDA: no
Description: No mouth guard (No MG)
Study: 15030966
Drug: Standard amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard amino acid solution (n = 10)
Study: 15030966
Drug: Branched chain
Normalized name: Branched Chain Amino Acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branched chain amino acid enriched solution (n = 10)
Study: 11474314
Drug: Amtolmetin‐guacyl (AMG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amtolmetin‐guacyl (AMG) 1200 mg for 2 days and 600 mg for 12 days
Study: 11474314
Drug: Piroxicam 40
Normalized name: piroxicam 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 40 mg for 2 days and 20 mg for 12 days
Study: 30993452
Drug: FACT-G Physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: FACT-G Physical Wellbeing
Study: 30993452
Drug: FACT-G Total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: FACT-G Total
Study: 29231475
Drug: Transcutaneous electrical
Normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous electrical nerve stimulation (TENS) at Neiguan (PC 6) and Zusanli (ST 36) for 4 weeks, 20 minutes twice a day.
Study: 29231475
Drug: Conventional medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medication and nursing (Control group).
Study: 21355447
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (levofloxacin 500 mg)
Study: 21355447
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (levofloxacin 500 mg)
Study: 16472797
Drug: 40 mg/d
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/d oral fluvastatin
Study: 16472797
Drug: 80 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/d oral fluvastatin
Study: 22803428
Drug: Routine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine therapy (Control)
Study: 12901033
Drug: Pantoprazole suspension
Normalized name: pantoprazole Oral Suspension
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pantoprazole suspension (20 mL of a suspension prepared from one crushed pantoprazole tablet and 840 mg of sodium bicarbonate solution)
Study: 12901033
Drug: Pantoprazole tablet
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pantoprazole tablet (one enteric-coated 40-mg pantoprazole tablet by mouth with 240 mL of water)
Study: 7318439
Drug: Chronic oral
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic oral contraceptive users (110 participants)
Study: 31661976
Drug: AEO (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: AEO (0.25 g/kg feed)
Study: 31661976
Drug: MOS (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOS (2 g/kg feed)
Study: 31661976
Drug: PRO (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRO (0.15 g/kg feed)
Study: 31661976
Drug: DEO (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEO (0.25 g/kg feed)
Study: 24837597
Drug: Cisplatin/5-fluorouracil 100/1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin/5-fluorouracil 100/1000 combined with panitumumab 9 mg/kg (Arm 1)
Study: 17694802
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose ketamine 0.3 mg/kg intravenously before the start of operation
Study: 17694802
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose ketamine 0.3 mg/kg intravenously at the end of operation
Study: 11549529
Drug: Fluticasone propionate-salmeterol
Normalized name: Fluticasone Propionate/Salmeterol Xinafoate 55 MCG/1 ACTUATION-14 MCG/1 ACTUATION Inhalation Powder [FLUTICASONE PROPIONATE-SALMETEROL XINAFOATE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate-salmeterol combination therapy (FSC) administered twice daily (100 microg of fluticasone propionate and 50 microg of salmeterol)
Study: 11549529
Drug: Fluticasone propionate-salmeterol
Normalized name: Fluticasone Propionate/Salmeterol Xinafoate 55 MCG/1 ACTUATION-14 MCG/1 ACTUATION Inhalation Powder [FLUTICASONE PROPIONATE-SALMETEROL XINAFOATE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate-salmeterol combination therapy (FSC) administered twice daily
Study: 15526805
Drug: Montelukast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (10 mg once daily)
Study: 8880657
Drug: Behavioral marital
Normalized name: barbital
DrugBank: Barbital (DB01483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral marital therapy (BMT)
Study: 9668941
Drug: Interactional couples
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactional couples therapy group
Study: 9668941
Drug: No-marital-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-marital-treatment control group
Study: 8062318
Drug: Extended-release ketoprofen
Normalized name: ketoprofen Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release ketoprofen 200 mg once daily for 3 weeks
Study: 8062318
Drug: Piroxicam 20
Normalized name: piroxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 20 mg once daily for 3 weeks
Study: 3546779
Drug: Oral diltiazem,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diltiazem, 180 mg/day
Study: 3546779
Drug: Oral verapamil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral verapamil, 240 mg/day
Study: 29484548
Drug: Active periodontal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active periodontal therapy (subgingival debridement); systemic antibiotics prescribed if Aggregatibacter actinomycetemcomitans was detected (10 AgP, 8 ChP); flap surgery if required.
Study: 24787491
Drug: Automated Self-Administered
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Automated Self-Administered 24-hour Recall (ASA24)
Study: 24787491
Drug: Interviewer-administered Automated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interviewer-administered Automated Multiple-Pass Method (AMPM)
Study: 21095264
Drug: Intravenous epoetin
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous epoetin α (up to 60,000 IU)
Study: 15951327
Drug: i.v. tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. tramadol 1.5 mg kg(‐1) and i.v. ketorolac 0.3 mg kg(‐1)
Study: 12460784
Drug: Ifosfamide 5
Normalized name: ifosfamide 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide 5 g/m(2) over 24 h (5 g/m(2)/1 day), every 3 weeks
Study: 12460784
Drug: Ifosfamide 3
Normalized name: ifosfamide 3000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide 3 g/m(2) per day over 4 h on three consecutive days (3 g/m(2)/3 days), every 3 weeks
Study: 12460784
Drug: Ifosfamide 5
Normalized name: ifosfamide 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide 5 g/m(2) over 24 h (5 g/m(2)/1 day), second-line treatment
Study: 12460784
Drug: Ifosfamide 3
Normalized name: ifosfamide 3000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide 3 g/m(2) per day over 4 h on three consecutive days (3 g/m(2)/3 days), second-line treatment
Study: 12460784
Drug: Ifosfamide 5
Normalized name: ifosfamide 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide 5 g/m(2) over 24 h (5 g/m(2)/1 day)
Study: 12460784
Drug: Ifosfamide 3
Normalized name: ifosfamide 3000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide 3 g/m(2) per day over 4 h on three consecutive days (3 g/m(2)/3 days)
Study: 7489439
Drug: Paracetamol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol plus ketorolac
Study: 1952133
Drug: Demand-dose PCEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demand-dose PCEA (3 mL every 10 min without restriction)
Study: 1952133
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion (CEI) (0.125% bupivacaine with fentanyl at 12 mL/h)
Study: 1952133
Drug: Demand-dose PCEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demand-dose PCEA
Study: 7030837
Drug: Prednisolone, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone, 40 mg given orally on alternate days
Study: 27390150
Drug: ABT-494 3
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-494 3 mg twice daily
Study: 27390150
Drug: ABT-494 6
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-494 6 mg twice daily
Study: 27390150
Drug: ABT-494 12
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-494 12 mg twice daily
Study: 27390150
Drug: ABT-494 18
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-494 18 mg twice daily
Study: 27390150
Drug: ABT-494 24
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-494 24 mg once daily
Study: 17941871
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg/day plus hypolipaemic diet
Study: 15982813
Drug: Alfentanil (plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (plasma concentration 70ng/ml)
Study: 15982813
Drug: Morphine high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine high dose (plasma concentration 30ng/ml)
Study: 15982813
Drug: Morphine low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine low dose (plasma concentration 15ng/ml)
Study: 19949319
Drug: All drugs
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All drugs tested
Study: 11263274
Drug: Xin Mai
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xin Mai Tong Capsule
Study: 6480127
Drug: Toluene (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toluene (50 ppm) and MEK (100 ppm) in combination
Study: 31783777
Drug: Brushing of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brushing of the palate and immersion of the prosthesis in 0.15% triclosan solution
Study: 31783777
Drug: Brushing of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brushing of the palate and immersion of the prosthesis in 0.25% sodium hypochlorite solution
Study: 27721534
Drug: rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 10 mg once a day for 12 weeks
Study: 22869566
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of liposomal amphotericin B/kg/day
Study: 22869566
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of liposomal amphotericin B/kg at time zero, followed by 5 mg/kg at 48 and 120 h
Study: 17208102
Drug: Palatal osseointegrated
Normalized name: malate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palatal osseointegrated implants combined with pendulum springs
Study: 1582124
Drug: Slow-releasing nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-releasing nicardipine (20 mg two times daily)
Study: 2417476
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (surgery and/or irradiation alone) - includes randomized control (RC) and concomitantly-treated (CC) patients
Study: 30756411
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 3 mL/kg 20% albumin over 30 minutes
Study: 29261824
Drug: Varenicline tartrate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline tartrate, 1 mg twice daily for 16 weeks
Study: 26688003
Drug: Low-dose rituximab
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rituximab (two 375-mg/m2 infusions)
Study: 26688003
Drug: Full-dose rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Full-dose rituximab (two 1000-mg infusions)
Study: 18194413
Drug: Prophylactic Antithrombin
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic Antithrombin Replacement in Kids with ALL treated with L‐Asparaginase (PARKAA) study
Study: 12773303
Drug: GLP-1 infusion
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 infusion for 60 min
Study: 30122620
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin at 1.8 mg/kg with gemcitabine 1000 mg/m2
Study: 27605258
Drug: Ilaprazole 10
Normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilaprazole 10 mg once daily
Study: 27605258
Drug: Ilaprazole 15
Normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilaprazole 15 mg once daily
Study: 22009525
Drug: Intravenous ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ciprofloxacin (CIP IV) 300 mg b.i.d.
Study: 22009525
Drug: Intravenous meropenem
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous meropenem (MEM IV) 500 mg b.i.d.
Study: 22009525
Drug: Intravenous ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ciprofloxacin (CIP IV) 300 mg b.i.d. in upper gastrointestinal surgery patients.
Study: 22009525
Drug: Intravenous meropenem
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous meropenem (MEM IV) 500 mg b.i.d. in upper gastrointestinal surgery patients.
Study: 18611150
Drug: Bacopa monnieri
Normalized name: BACOPA MONNIERI WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacopa monnieri extract 300 mg/day
Study: 17318006
Drug: Pharmacotherapy (PHT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy (PHT)
Study: 15730064
Drug: Prolonged Exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged Exposure (PE) alone or in combination with cognitive restructuring
Study: 11726307
Drug: Potassium chloride
Normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium chloride (KCl) containing chewing gum used up to 6 times daily for 10 min each occasion for 3 weeks
Study: 11764019
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg methylphenidate (MPH)
Study: 9234034
Drug: Expectancy regarding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expectancy regarding medication
Study: 7685719
Drug: Local injection
Normalized name: Sclerosing agents for local injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local injection of hyperosmolar (50%) glucose solution
Study: 30932134
Drug: 2RDA (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2RDA (2 times the recommended daily allowance of protein intake, 2g/kg/d)
Study: 30932134
Drug: RDA (current
Approvals — FDA: no, EMA: no, PMDA: no
Description: RDA (current recommended daily allowance of protein intake, 0.8g/kg/d)
Study: 24772415
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate 65 mg kg(‐1) infusion in 250 mL 5% dextrose at 3.5 mL/min (Group M)
Study: 24772415
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate 65 mg kg(‐1) infusion (Group M)
Study: 18608623
Drug: Family Weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family Weight School therapy program in group meetings
Study: 12468603
Drug: Cracker with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cracker with cream cheese
Study: 12468603
Drug: Oral stimulation
Normalized name: follicle stimulating hormone / luteinizing hormone Injection [Menopur]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral stimulation by fat
Study: 12468603
Drug: Safflower oil
Normalized name: Safflower Oil
DrugBank: Safflower oil (DB09446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safflower oil capsules
Study: 10369171
Drug: Group Cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Cognitive Behaviour Therapy (CBT) during hospital rehabilitation
Study: 7547095
Drug: Tenidap sodium
Normalized name: tenidap sodium
DrugBank: Tenidap (DB13481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenidap sodium (120 mg day‐1)
Study: 7009093
Drug: Poly A.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poly A. Poly U I.V. 30 mg per week for 6 weeks
Study: 19067673
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg daily for 8 weeks
Study: 28692586
Drug: Extended-release metformin
Normalized name: metformin Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release metformin
Study: 22166651
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus metformin (0.5 g, tid)
Study: 22166651
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus metformin (0.5 g, tid) and pioglitazone (15 mg, qd)
Study: 11092645
Drug: HRT 2
Normalized name: EE/NETHDRONE (EQV-FEMHRT 2.5/0.5) TAB,28
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT 2 (1 mg 17beta‐estradiol plus 0.025 mg gestodene for 12 days every third month)
Study: 11092645
Drug: HRT 1
Normalized name: FEMHRT 1/5 TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT 1 (1 mg 17beta‐estradiol plus 0.025 mg gestodene for 12 days every month)
Study: 27171844
Drug: Oxandrolone (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone (0.1 mg/kg twice/day for 12 months)
Study: 15917280
Drug: Education on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education on oral anticoagulation, anticoagulation files, and patient information booklets; Group B received feedback every 2 months; Group C used CoaguChek device; Group D received Dawn AC computer assisted advice
Study: 15917280
Drug: Education on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education on oral anticoagulation, anticoagulation files, and patient information booklets
Study: 12546514
Drug: 5-aminosalicylic acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminosalicylic acid tablets 2.4 g/day and enema 2 g/day for 4 weeks
Study: 12546514
Drug: 5-aminosalicylic acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminosalicylic acid tablets 2.4 g/day and enema 2 g/day for 8 weeks
Study: 12546514
Drug: Oral mesalazine
Normalized name: mesalamine Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mesalazine alone at 1.2 g/day during maintenance period
Study: 12546514
Drug: 5-aminosalicylic acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminosalicylic acid tablets 2.4 g/day and enema 2 g/day for 8 weeks (specifically for left-sided colitis)
Study: 2690913
Drug: Intravenous adriamycin
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous adriamycin 50 mg, vincristine 1 mg, cyclophosphamide 250 mg, methotrexate 150 mg and fluorouracil 250 mg (AVCMF) every 21 days for eight cycles
Study: 1155990
Drug: Tetrachlorethylene (T.C.E.)
Normalized name: trichloroethylene
DrugBank: Trichloroethylene (DB13323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetrachlorethylene (T.C.E.) - single dose
Study: 1155990
Drug: Bephenium hydroxynaphthoate
Normalized name: Bephenium hydroxynaphthoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bephenium hydroxynaphthoate - single dose
Study: 1155990
Drug: Pyrantel pamoate
Normalized name: Pyrantel Pamoate
DrugBank: Pyrantel (DB11156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrantel pamoate - single dose
Study: 1155990
Drug: Bephenium hydroxynaphthoate
Normalized name: Bephenium hydroxynaphthoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bephenium hydroxynaphthoate - three daily doses
Study: 1155990
Drug: Pyrantel pamoate
Normalized name: Pyrantel Pamoate
DrugBank: Pyrantel (DB11156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrantel pamoate - three daily doses
Study: 31901090
Drug: Cold analgesic
Normalized name: MENTHOL 1 g in 100 g TOPICAL GEL [Ice Cold Analgesic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold analgesic technique
Study: 31901090
Drug: Vibration analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibration analgesic technique
Study: 31901090
Drug: No-treatment arm
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment arm (Control)
Study: 22764364
Drug: Naltrexone implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone implant
Study: 30880163
Drug: Oral naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral naltrexone placebo
Study: 29283224
Drug: Autonomic regulation
Normalized name: AUTONOMIC MEDICATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autonomic regulation therapy (ART) using right cervical vagus nerve stimulation (VNS)
Study: 20615781
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl and propofol (group B)
Study: 11788429
Drug: Intravenous terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous terbutaline
Study: 11426091
Drug: Intravenous normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous normal saline (placebo)
Study: 8923125
Drug: Tricyclic Antidepressants
Normalized name: TRICYCLIC ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricyclic Antidepressants (TCAs)
Study: 2524114
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of diflunisal and cyclobenzaprine HCl
Study: 71492
Drug: High-potency antilymphocyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-potency antilymphocyte globulin (A.L.G.)